Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072482 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
A Phase 4 study of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06072482 is a Phase 4 study of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis that is actively recruiting participants, run by Amgen. The registered enrollment target is 300 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT06072482, a Phase 4 study of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Standard of Care
- DRUG Avacopan
Study Locations (20)
California
- Medvin Clinical Research - Covina
- Palo Alto Medical Foundation Fremont - Fremont
- The Nephrology Group - Fresno
- Providence Medical Foundation - Fullerton
- Medvin Clinical Research - Menifee
- University of California San Francisco- Zuckerburg San Francisco General - San Francisco
- Harbor University of California at Los Angeles Medical Center - Torrance
Florida
- Florida Kidney Physicians - Boca Raton
- Malcom Randall Veterans Affairs Medical Center - Gainesville
- Mayo Clinic - Jacksonville
- ClinTrial Research Oakwater, Llc - Orlando
- University of South Florida - Tampa
Arizona
- Scottsdale Healthcare at Shea - HonorHealth - Scottsdale
- Southwest Kidney Institute - Surprise
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
- Dunes Clinical Research LLC - Sioux City
Alaska
- Orthopedic Physicians Alaska - Anchorage
Colorado
- University of Colorado - Aurora
Georgia
- Emory University - Atlanta
Indiana
- Lake Cumberland Rheumatology - New Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2036-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072482
The ClinicalTrials.gov registry entry for NCT06072482 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06072482 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06072482 about?
NCT06072482 is a clinical study titled "A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis". The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
What is the current status of trial NCT06072482?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2024-02-07. Estimated completion is 2036-12-31.
What conditions does trial NCT06072482 study?
This clinical trial studies the following conditions: Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT06072482?
The interventions under investigation include: Placebo (DRUG), Standard of Care (DRUG), Avacopan (DRUG).
Who is sponsoring clinical trial NCT06072482?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072482 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.